Note: The full article and accompanying features are only available whilst being signed in.
Summary
In this current marketing, medical and economic climate, Pharmaceutical companies are seeking different ways to optimize the launch of new, specialist products and produce additional revenue. As such, a growing number of European and US companies are recognizing the potential of using pre-launch Named Patient Programs (NPP) as part of their global market access strategy to generate significant financial and non-financial benefits for a product launch.
New results from a recent study conducted by Eularis found that implementing pre-launch NPPs had a significant effect on the cash market share of a drug within the first year of launch.
Want more?
The content of this page been summarized. To view the full content, please register or sign in to the Eularis web site.
Register with Eularis
or
Sign in